Literature DB >> 19416084

Pharmacokinetics and pharmacodynamics of antimicrobial drugs.

David Czock1, Christoph Markert, Bertram Hartman, Frieder Keller.   

Abstract

BACKGROUND: Antimicrobial drugs exhibit different characteristics in their correlation between antimicrobial drug concentrations and effects on microorganisms. These correlations have been studied using different approaches including in vitro analyses with constant and fluctuating concentrations and in vivo analyses involving animals and humans. Mathematical analysis includes correlation of pharmacokinetic-pharmacodynamic (PK-PD) indices to an outcome parameter. Further insight can be gained by mechanism-based modelling of antimicrobial drug effects. METHODS AND
RESULTS: This review aims to provide an overview on the various approaches used to analyse antimicrobial pharmacodynamics, to discuss the limitations of these approaches, to indicate recent developments and to summarise the current knowledge on PK-PD target values as derived from human studies.
CONCLUSION: It is expected that PK-PD analysis of antimicrobial drug effects will lead to a more efficient and possibly also less toxic antimicrobial drug therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416084     DOI: 10.1517/17425250902913808

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  15 in total

Review 1.  Drug therapy in patients with chronic renal failure.

Authors:  Bertram Hartmann; David Czock; Frieder Keller
Journal:  Dtsch Arztebl Int       Date:  2010-09-17       Impact factor: 5.594

2.  Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example.

Authors:  Tomas Radivoyevitch; Nopphon Siranart; Lynn Hlatky; Rainer Sachs
Journal:  AAPS J       Date:  2015-02-07       Impact factor: 4.009

3.  Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.

Authors:  Christian Bustamante; Rodrigo Ochoa; Claudia Asela; Carlos Muskus
Journal:  J Comput Aided Mol Des       Date:  2019-10-14       Impact factor: 3.686

4.  Suboptimal antimicrobial drug exposure in patients with renal impairment.

Authors:  David Czock; Martino Spitaletta; Frieder Keller
Journal:  Int J Clin Pharm       Date:  2015-05-28

5.  Theoretical investigation of stochastic clearance of bacteria: first-passage analysis.

Authors:  Hamid Teimouri; Anatoly B Kolomeisky
Journal:  J R Soc Interface       Date:  2019-03-29       Impact factor: 4.118

6.  [Questionnaire surveying nephrologists on drug dose adjustment in patients with impaired kidney function].

Authors:  Sebastian Maus; Caecilia Holch; David Czock; Florian Thalhammer; Frieder Keller; Bertram Hartmann
Journal:  Wien Klin Wochenschr       Date:  2010-08-04       Impact factor: 1.704

Review 7.  [Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI].

Authors:  D Czock; V Schwenger; D Kindgen-Milles; M Joannidis; S John; M Schmitz; A Jörres; A Zarbock; M Oppert; J T Kielstein; C Willam
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-03-15       Impact factor: 0.840

8.  Semimechanistic Modeling of Eravacycline Pharmacodynamics Using In Vitro Time-Kill Data with MIC Incorporated in an Adaptive Resistance Function.

Authors:  Ken Nguyen; Timothy J Bensman; Xiaohui Tracey Wei; Jason N Moore
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

9.  [Musculoskeletal infections in the era of multiresistant pathogens].

Authors:  T Grünewald; B R Ruf
Journal:  Unfallchirurg       Date:  2012-06       Impact factor: 1.000

Review 10.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.